Recent Updates
Recently added Catalysts

20/20 Biolabs, Inc.

AIDXFDA catalysts, PDUFA dates & pipeline intelligence
$0.19
▼ -0.02 · -9.45%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full AIDX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.5152W HIGH $50.00
Volume
138.06 K
Value Traded
26.19 K
Short % Float
0.64%
Days to Cover
1.0
-7.5%Week
-28.93%1 Month
-66.38%3 Month
-85.98%6 Month

Cash Data

Unlock AIDX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
2.47 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-2.07 M
Total Shares
13.37 M
Float Shares
8.87 M
Insiders
33.61%
Institutions
3.57%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every AIDX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

AIDX Catalyst Timeline

Dated clinical, regulatory and corporate events for 20/20 Biolabs, Inc.

Unlock the full AIDX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How AIDX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all AIDX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

20/20 Biolabs, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every AIDX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every AIDX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock AIDX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Bergman Alan B.Officer (Chief Financial Officer)Grant/Award 100,000 100,000 held$0.00 04/02/2026
Unlock the full AIDX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in AIDX for Q2 2026.
Unlock every fund holding AIDX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in AIDX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see AIDX ownership
Insider and institutional ownership, quarter by quarter.

AIDX Short Interest

Shares sold short, counted twice a month.

0.64%
Short % of Float
of tradable shares sold short
57.0K
Shares Sold Short
+405.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
160.3K
Avg Daily Volume
the average used for days to cover
Unlock AIDX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock AIDX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live AIDX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock AIDX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How AIDX ranks across every disease it competes in

Competitive Position is a premium feature
See how AIDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

AIDX News

-AIDX
Nov 16, 2026
AIDXGeneral
▼ -9.4%today

20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates

20/20 BioLabs reported a 4.1% revenue increase to $1.36 million for the first nine months of 2026. The company secured a two-year cancer screening contract with Vermont, expected to boost revenue in Q4. However, third quarter revenue fell to $0.38 million, and net loss increased to $1.38 million, reflecting operational challenges.

Read more →
-AIDX
Nov 5, 2026
AIDXGeneral
▼ -18.3%on this news

REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026

20/20 BioLabs has called for stockholders to vote at the Special Meeting on December 9, 2026. Key proposals include authorization for a reverse stock split to meet Nasdaq's minimum bid price requirement. Stockholders of record as of October 20, 2026, can vote online or via phone. The Board encourages participation to ensure a quorum.

Read more →
-AIDX
Oct 29, 2026
AIDXConferences/Events
▼ -6.4%on this news

20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy

20/20 BioLabs will host an investor webinar on November 4, 2026, led by CEO Jonathan Cohen. The discussion will cover plans for expanding OneTest™ through licensing and acquisitions, FDA strategies, and initiatives for firefighter cancer screening. The company aims to enhance its commercial reach and address investor questions during the session.

Read more →
-AIDX
Oct 2, 2026
AIDXConferences/Events
▼ -7.1%on this news

20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026

20/20 BioLabs, Inc. will participate in the Maxim Growth Summit 2026 on October 14, 2026, at the Hard Rock Hotel New York. CEO Jonathan Cohen and CFO Alan Bergman will hold one-on-one meetings with institutional investors. The summit aims to showcase the company's AI-powered blood tests for early cancer and chronic disease detection.

Read more →
-AIDX
Sep 29, 2026
AIDXConferences/Events

20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model

20/20 BioLabs is hosting an investor webinar on October 7, 2026, to discuss the implications of a recent FDA advisory committee vote on multi-cancer early detection tests. CEO Jonathan Cohen will outline the company's new OneTest™ franchise model and the preliminary interest from laboratories. The webinar aims to provide insights into regulatory strategies and new funding initiatives for cancer screening.

Read more →
-AIDX
Aug 28, 2026
AIDXConferences/Events

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

20/20 BioLabs has rescheduled its investor webinar to September 2, 2026, at 2:00 p.m. ET. CEO Jonathan Cohen will discuss the company's record revenue for OneTest™ and insights from the Next Generation Dx Summit. The webinar will cover the company's growth strategies and the evolution of its testing platform, along with a Q&A session.

Read more →
-AIDX
Aug 26, 2026
AIDXConferences/Events
▲ +6.6%on this news· ran to +17% by day 1shared move

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

20/20 BioLabs will host an investor webinar on September 2, 2026, to discuss its record revenue and commercial strategies. CEO Jonathan Cohen will highlight the company's second quarter results, including a 47.1% increase in OneTest™ revenue. The webinar will also cover key insights from the Next Generation Dx Summit and the evolution of the OneTest™ platform.

Read more →
-AIDX
Aug 17, 2026
AIDXGeneral

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

20/20 BioLabs reported strong financial results for Q2 2026, with OneTest™ revenue reaching $0.7 million, a 47% increase year-over-year. The company expanded its market reach and eliminated all convertible note debt, strengthening its cash position to $4.5 million. Despite a net loss of $1.5 million, the operational metrics indicate significant growth and improved profitability.

Read more →
-AIDX
Jul 30, 2026
AIDXConferences/Events
▼ -8.5%on this news

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

20/20 BioLabs will host an investor webinar on August 5, 2026, to discuss insights from its recent East Asia business development tour. CEO Jonathan Cohen will cover the company's participation in BIO Asia-Taiwan and its strategic meetings in Taipei, Tokyo, and Seoul. The webinar will also address the company's East Asia roll-up strategy and opportunities for commercialization.

Read more →
-AIDX
Jul 27, 2026
AIDXGeneral

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

20/20 BioLabs participated in BIO Asia-Taiwan and held strategic meetings in East Asia to explore acquisition and partnership opportunities. The company aims to enhance its mission of early disease detection through collaborations with local firms. CEO Jonathan Cohen emphasized the importance of these relationships for achieving Medicare reimbursement for their multi-cancer early detection test by 2028.

Read more →
-AIDX
Jul 23, 2026
AIDXGeneral
▼ -6.8%on this news· ran to -17% by day 3shared move

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

20/20 BioLabs has entered a standstill agreement with Streeterville Capital regarding its Series E Convertible Preferred Stock. This agreement restricts the conversion of preferred stock into common stock unless certain price thresholds are met, thereby mitigating potential dilution. The agreement is effective for 120 days, after which normal conversion activities may resume.

Read more →
-AIDX
Jul 9, 2026
AIDXConferences/Events

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

20/20 BioLabs presented its strategy for advancing OneTest™ for Cancer during an investor webinar. The company aims to position the test for Medicare reimbursement under new legislation for multi-cancer early detection blood tests. While the approach shows promise, it faces significant regulatory hurdles, including the need for FDA authorization and CMS coverage determinations.

Read more →
-AIDX
Jun 22, 2026
AIDXConferences/Events

20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

20/20 BioLabs has announced a new monthly investor webinar series starting July 1, 2026. The initiative aims to enhance transparency and communication with shareholders by providing direct access to management. Each session will last approximately 45 minutes and will include updates on the company's progress. Attendees will receive a promotional discount for a blood test.

Read more →
-AIDX
May 22, 2026
AIDXGeneral
▼ -18.7%on this news

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

20/20 Biolabs is preparing for potential Ebola and Hantavirus testing in response to recent outbreaks. Drawing on its COVID-19 testing experience, the company is developing contingency plans and engaging with global PCR test kit developers. This proactive approach aims to ensure readiness for any surge in testing demands, although no regulatory authorization has been granted yet.

Read more →
-AIDX
May 20, 2026
AIDXGeneral

BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026

20/20 BioLabs, Inc. (AIDX) reported its first quarter financial results for 2026, highlighting a decrease in revenue to $0.4 million. The company noted a significant $5.0 million private placement aimed at strengthening its cash position to $4.2 million. Noteworthy operational progress includes new distribution agreements and the launch of the OneTest for Longevity product. Despite a loss of $2.2 million during the quarter, the projected expansion of firefighter cancer screening initiatives is expected to drive future revenue growth.

Read more →
-AIDX
Mar 31, 2026
AIDXGeneral
▲ +5.6%on this news

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

20/20 BioLabs, Inc. reported its financial results for FY 2025, highlighting a 17% revenue increase to $2.0 million and a significant gross profit rise of 68%. The company's gross margin expanded notably, driven by the success of its OneTest suite of products in the expanding Multi-Cancer Early Detection (MCED) market. Despite improvements, the company also recorded a net loss of $3.7 million. Future growth is anticipated through state-funded cancer screening initiatives and new offerings such as the OneTest for Longevity.

Read more →
-AIDX
Mar 27, 2026
AIDXGeneral

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test

20/20 BioLabs announced that 18 Maryland fire departments will receive over $520,000 for cancer screenings using their OneTest™ multi-cancer early detection blood test. This funding, part of a state initiative, aims to screen over 1,400 firefighters, highlighting the growing support for innovative cancer detection. The initiative reflects a 225% increase in funding compared to the previous year.

Read more →
-AIDX
Mar 24, 2026
AIDXGeneral
▼ -17.6%on this newsshared move

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

20/20 BioLabs has entered an exclusive U.S. license agreement with ROKIT Healthcare to incorporate a chronic kidney disease (CKD) prediction algorithm into its Longevity Platform. This partnership aims to enhance disease-risk assessment tools, potentially improving therapeutic outcomes for patients. The agreement also includes provisions for ROKIT to commercialize the platform in Korea and other East Asian markets.

Read more →
-AIDX
Feb 25, 2026
AIDXGeneral
▼ -28.8%on this news· ran to -58% by day 3

20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities

20/20 BioLabs has launched the OneTest for Longevity, a blood test that uses IBM's AI technology to assess chronic disease risks. This test analyzes inflammatory biomarkers and provides personalized dietary recommendations. The collaboration with DAISource aims to enhance healthcare applications through AI. However, the test is not FDA approved.

Read more →
-AIDX
Feb 20, 2026
AIDXConferences/Events
▼ -38%on this news· ran to -76% by day 3shared move

20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time

20/20 BioLabs, Inc. will hold a virtual investor webinar on February 26, 2026, at 2:00 p.m. ET. CEO Jonathan Cohen will discuss the company's recent Nasdaq listing and its AI-powered blood tests, including the OneTest for Cancer and the upcoming OneTest for Longevity. A Q&A session will follow the presentation.

Read more →

About 20/20 Biolabs, Inc.

Rockville, MD 14 employees 2020biolabs.com
Headquarters9430 KEY WEST AVENUE, ROCKVILLE, MD, 20850
BIOPHARMAWATCH ELITE
Trade the next AIDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime